Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 10:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blister Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prevention Trial Assessing Paper-Tape in Endurance Distances II (Pre-TAPED II)

NCT01945112
View directory record Official record
Conditions
Blister of Foot
Interventions
Paper Tape
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 8, 2026, 10:30 AM EDT
Terminated Not applicable Interventional Results available

Clinical Trial to Evaluate Blister Graft Utilizing a Novel Harvesting Device for Treatment of Venous Leg Ulcers

NCT02148302
View directory record Official record
Conditions
Impaired Wound Healing, Venous Insufficiency of Leg, Diabetic Ulcers
Interventions
Harvesting Device (CelluTome©)
Device
Lead sponsor
SerenaGroup, Inc.
Network
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Boca Raton, Florida • Homestead, Florida • Largo, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Sep 8, 2026, 10:30 AM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris

NCT01930175
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
VAY736, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
20 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Sep 8, 2026, 10:30 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid

NCT02226146
View directory record Official record
Conditions
Pemphigoid, Bullous
Interventions
Bertilimumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Iowa City, Iowa • Buffalo, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 8, 2026, 10:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Visual Distraction as a Means of Enhancing Child Resistance

NCT01859780
View directory record Official record
Conditions
Unintentional Ingestion of Prescriptions Within Vials and Blisters
Interventions
Visual distractor
Other
Lead sponsor
Michigan State University
Other
Eligibility
2 Years to 54 Months
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
East Lansing, Michigan • Howell, Michigan • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 8, 2026, 10:30 AM EDT
Not listed Not applicable Interventional

Use of the Epidermal Micrografts for Wound Healing After Mohs or Excisional Surgery for Skin Cancer

NCT01536444
View directory record Official record
Conditions
Neoplasm of Skin
Interventions
Momelan Technologies Epidermal Graft Harvesting System
Device
Lead sponsor
Momelan Technologies
Industry
Eligibility
35 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 8, 2026, 10:30 AM EDT
Completed Phase 4 Interventional

Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs

NCT00392275
View directory record Official record
Conditions
Cataract
Interventions
Ofloxacin 0.3%, Ciprofloxacin 0.3%, Levofloxacin 0.5%, Ofloxacin 400mg, Ciprofloxacin 400mg, Levofloxacin 250mg
Drug
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Sep 8, 2026, 10:30 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?

NCT00853073
View directory record Official record
Conditions
Glaucoma
Interventions
bevacizumab, balanced salt solution
Drug · Other
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Sep 8, 2026, 10:30 AM EDT
Completed Not applicable Interventional

Blister Packaging Medication to Increase Treatment Adherence and Clinical Response

NCT01118208
View directory record Official record
Conditions
Medication Adherence, Accidental Overdose, Deliberate Overdose, Suicide, Attempted
Interventions
Blister packaging medications, Dispense as usual
Other
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Sep 8, 2026, 10:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid

NCT00584935
View directory record Official record
Conditions
Ocular Cicatricial Pemphigoid
Interventions
Rituximab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 8, 2026, 10:30 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.

NCT04612790
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Centennial, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 8, 2026, 10:30 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex

NCT05062070
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
TolaSure Topical Gel, Vehicle Topical Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 8, 2026, 10:30 AM EDT
Completed No phase listed Observational

An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin

NCT00923104
View directory record Official record
Conditions
Breast Cancer, Healthy Volunteer, Prostate Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 8, 2026, 10:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers

NCT00001150
View directory record Official record
Conditions
Dermatitis, Healthy, Neoplasm, Urticaria, Vesiculobullous Skin Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1976 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 8, 2026, 10:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Immune Response in Normal Volunteers and Patients With Helminth Infections

NCT00004996
View directory record Official record
Conditions
Healthy, Helminthiasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 8, 2026, 10:30 AM EDT
Completed No phase listed Observational

Registry for Vascular Anomalies Associated With Coagulopathy

NCT00576888
View directory record Official record
Conditions
Multifocal Lymphangioendotheliomatosis With Thrombocytopenia, Cutaneovisceral Angiomatosis With Thrombocytopenia, Vascular Anomaly With Thrombocytopenia, Hemangiomas
Interventions
no intervention
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 8, 2026, 10:30 AM EDT
Terminated Not applicable Interventional Results available

Botulinum Toxin A for Herpes Labialis

NCT01225341
View directory record Official record
Conditions
Herpes Labialis
Interventions
onabotulinumtoxinA, Bacteriostatic normal saline
Drug · Other
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 8, 2026, 10:30 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses

NCT00001257
View directory record Official record
Conditions
Healthy Volunteers, Abnormal Phagocyte Function
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 65 Years
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1990 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 8, 2026, 10:30 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

NCT05535738
View directory record Official record
Conditions
Skin Inflammation, Allergic Contact Dermatitis
Interventions
Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab, Adalimumab, Ustekinumab, Guselkumab, Canakinumab, Sarilumab, Triamcinolone Acetonide, Betamethasone Valerate, Fluticasone Propionate, Microneedle, Suction blistering, Skin punch biopsy
Drug · Other · Device + 1 more
Lead sponsor
Wei-Che Ko
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 8, 2026, 10:30 AM EDT
Not yet recruiting Not applicable Interventional

Opioid Package Prototype (OPP)

NCT04598074
View directory record Official record
Conditions
Opioid Use, Opioid Prescribing, Dispensing, and Patient Use
Interventions
Opioid Package Prototype (OPP), Usual Care (standard amber vial)
Other
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 8, 2026, 10:30 AM EDT
Active, not recruiting Not applicable Interventional

Safety of the Sonablate HIFU System for the Ablation of Incompetent Veins of the Periphery

NCT06642051
View directory record Official record
Conditions
Chronic Venous Insufficiency, CVI, Venous Malformations, Venous Leg Ulcers, Klippel-Trenaunay Syndrome, CLOVES Syndrome, Blue Rubber Bleb Nevus Syndrome
Interventions
High Intensity focused ultrasound
Device
Lead sponsor
Sonablate
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Darien, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 8, 2026, 10:30 AM EDT
Withdrawn Phase 3 Interventional

Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)

NCT05061771
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
nomacopan (rVA576), Placebo
Drug · Other
Lead sponsor
AKARI Therapeutics
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Los Angeles, California • Skokie, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 8, 2026, 10:30 AM EDT
Completed Phase 2 Interventional Results available

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

NCT02960997
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner, Weber-Cockayne Syndrome
Interventions
Sirolimus, 2%, Vehicle
Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 8, 2026, 10:30 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pro-Resolving Mediators in Acute Inflammation in Humans

NCT04308889
View directory record Official record
Conditions
Inflammation; Skin, Resolution, Blister
Interventions
Lovaza, Cantharone, Phlebotomy
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 8, 2026, 10:30 AM EDT